FrancophonIA/ELRC3.0 huggingface dataset:
English: The MAH shall submit an updated risk management plan (RMP) that adequately describes the additional pharmacovigilance activity of performing an embryo-foetal developmental toxicity study in cynomolgus monkeys to further investigate the
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq (MAH) ser jissottometti pjan tal-immaniġġjar tar-riskju (RMP) aġġornat li jiddeskrivi b'mod adegwat l-attività addizzjonali ta' farmakoviġilanza tat-twettiq ta' studju tat-tossiċità tal-iżvilupp fil-fetu fix-xadini cynomolgus sabiex jinvestiga aktar ir-riskju potenzjali ta' difetti fil-fetu.
English: Do not use Rilonacept Regeneron after the expiry date.
Maltese: Tużax Rilonacept Regeneron wara d-data ta' skadenza.
English: Table 1: Rilonacept Regeneron dose volume (after reconstitution) by body weight for paediatric patients, aged 12-17 years
Maltese: Tabella 1: Volum tad-doża ta' Rilonacept Regeneron (wara r-rikostituzzjoni) skont il-piż tal-ġisem għal pazjenti pedjatriċi li għandhom minn 12 sa 17-il sena
English: The efficacy was not evaluated in patients without a confirmed NLRP3/CIAS1 gene mutation.
Maltese: L-effikaċja ma kinitx evalwata f'pazjenti mingħajr konferma ta' mutazzjoni tal-ġeni NLRP3/CIAS1.
English: Should vaccination with live vaccines be indicated after initiation of Rilonacept Regeneron treatment, the recommendation is to wait for at least 6 weeks after the last Rilonacept Regeneron injection and before the next one (see section 4.4).
Maltese: Fil-każ li tilqima b'tilqim ħaj tkun indikata wara l-bidu tal-kura b'Rilonacept Regeneron, ir-rakkomandazzjoni hi li tistenna għal mill-inqas 6 ġimgħat wara l-aħħar injezzjoni ta' Rilonacept Regeneron u qabel dik li jkun imiss (ara sezzjoni 4.4).
English: Open the wrapper that contains a syringe by pulling apart the tabs.
Maltese: Fi studju mtawwal tat-tip open-label, pazjent wieħed żviluppa meninġite batterjali u miet.
English: Baseline Mean KSS
Maltese: KSS medja filLinja Bażi
English: 8 disposable 3 ml syringes 8 disposable 27 gauge, ½-inch needles
Maltese: 8 siringi ta' 3 ml li jintremew wara li jintużaw 8 labriet ta' qies 27, ta' ½ pulzier li jintremew wara li jintużaw
English: For storage conditions after reconstitution of the medicinal product, see section 6.3.
Maltese: Għall-kondizzjonijiet tal-ħażna wara r-rikostituzzjoni tal-prodott mediċinali, ara sezzjoni 6.3.
English: Live vaccines should not be given concurrently with Rilonacept Regeneron (see section 4.5).
Maltese: Tilqim ħaj m'għandux jingħata fl-istess ħin ma' Rilonacept Regeneron (ara sezzjoni 4.5).
English: PHARMACEUTICAL PARTICULARS
Maltese: Brecon Pharmaceuticals
English: - fever lasting longer than 3 days, or any other symptoms possibly related to an infection, such as prolonged cough, prolonged headache or localised redness, warmth or swelling of your skin.
Maltese: • deni li jdum iktar minn 3 ijiem, jew kwalunkwe sintomi oħrajn possibbilment marbuta ma' infezzjoni, bħal sogħla fit-tul, uġigħ ta' ras jew ħmura lokalizzata li jdumu; sħana jew nefħa fil-ġilda tiegħek.
English: Week 24 Mean KSS
Maltese: KSS medja f'Ġimgħa 24
English: Bronchitis; gastroenteritis; viral infections; skin, eye and ear infections; pneumonia Bacterial meningitis
Maltese: Bronkite; gastroenterite; infezzjonijiet virali; infezzjonijiet fil-ġilda, fl-għajnejn u fil-widnejn; pnewmonja komuni
English: The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP).
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq (MAH) għandu jwettaq l-attivitajiet ta' farmakovigilanza kif deskritt fil-Pjan ta' Farmakoviġilanza kif inhu maqbul fil-RMP ppreżentat f'Modulu 1.8.2 tal-Awtorizzazzjoni għat-Tqegħid fis-Suq u kwalunkwe aġġornament sussegwenti talRMP kif maqbul mill-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP).
English: p-value for within group comparison of change from Baseline p< 0.0001 NS
Maltese: Valur p bi skop ta' paragun fi ħdan ilgrupp, tal-bidla mil-Linja bażi p< 0.0001 NS
English: However, clinical experience in patients above 65 years is limited, therefore caution is recommended.
Maltese: Madankollu, l-esperjenza klinika f'pazjenti li għandhom iktar minn 65 sena hi limitata, u għalhekk il-kawtela hi rakkomandata.
English: Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and repeated-dose toxicity.
Maltese: Informazzjoni mhux klinika, magħmula fuq studji konvenzjonali ta' sigurtà farmakoloġika u effett tossiku minn dożi ripetuti, ma turi l-ebda periklu speċjali għall-bnedmin.
English: Further PK steady state exposure data (AUC, Cmax, Cmin during steady state) especially for paediatric subjects is required.
Maltese: Hi meħtieġa dejta addizzjonali dwar il-PK tal-espożizzjoni fl-istat fiss (AUC, Cmax, Cmin matul l-istat fiss) speċjalment għal pazjenti tfal..
English: Table 5: Rilonacept steady-state pharmacokinetic properties1
Maltese: PASS 1: Kif tipprepara għall-injezzjoni
English: There was no correlation of antibody activity and either clinical efficacy or safety.
Maltese: Ma kien hemm l-ebda korrelazzjoni ta' attività tal-antikorpi mal-effikaċja klinika jew mas-sigurtà.
English: Package leaflet: Information for the user Rilonacept Regeneron 80 mg/ml powder and solvent for solution for injection rilonacept
Maltese: Rilonacept Regeneron 80 mg/ml trab u solvent għal soluzzjoni għall-injezzjoni
English: Remove the syringe and needle from the stopper and throw away the syringe attached to the needle and sterile water (solvent) vial in the puncture-resistant container.
Maltese: Neħħi s-siringa u l-labra mit-tapp u armi s-siringa mwaħħla mal-labra u l-kunjett bl-ilma sterili (solvent) fil-kontenitur li ma jittaqqabx.
English: Blood and lymphatic system disorder
Maltese: Disturbi tad-demm u tas-sistema limfatika
English: Age group (range)
Maltese: Grupp ta' (medda)
English: Fatigue common
Maltese: Sturdament komuni
English: Part A
Maltese: NUMRU(I)
English: STEP 2: Preparing the vial of Rilonacept Regeneron powder Remove the plastic cap from the Rilonacept Regeneron vial.
Maltese: Neħħi l-għatu tal-plastik minn fuq il-kunjett b'Rilonacept Regeneron.
English: Consequently, impaired liver function is not expected to affect the pharmacokinetics of rilonacept in a clinically significant way.
Maltese: Konsegwentement, l-indeboliment filfunżjoni tal-fwied mhux mistenni li jaffettwa l-farmakokinetika ta' rilonacept b'mod li hu klinikament sinifikanti.
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Maltese: Prodott mediċinali li jingħata b'riċetta ristretta tat-tabib (Ara Anness I: Sommarju tal-Karatteristiċi talProdott, sezzjoni 4.2).
English: Attach the exposed top of the sterile water vial to the top of a syringe by twisting the syringe onto the vial of sterile water (solvent) (see Figure 2).
Maltese: Waħħal in-naħa esposta ta' fuq tal-kunjett tal-ilma sterili man-naħa ta' fuq ta' siringa billi ddawwar is-siringa fuq il-kunjett tal-ilma sterili (solvent) (ara Figura 2).
English: The solvent is a colourless liquid.
Maltese: Is-solvent hu ilma għall-injezzjonijiet.
English: How to inject Rilonacept Regeneron
Maltese: Mediċini oħra u Rilonacept Regeneron
English: Women should use effective contraceptives during treatment with Rilonacept Regeneron and for up to 6 weeks after the last dose.
Maltese: In-nisa għandhom jużaw kontraċettivi effettivi waqt il-kura b'Rilonacept Regeneron u sa 6 ġimgħat wara l-aħħar doża.
English: PHARMACEUTICAL FORM Powder and solvent for solution for injection.
Maltese: 3. GĦAMLA FARMAĊEWTIKA Trab u solvent għal soluzzjoni għall-injezzjoni.
English: Hold the barrel of the syringe with one hand and twist the 27-gauge needle onto the tip of the syringe with the other hand until it fits snugly (see Figure 4).
Maltese: Żomm il-bettija tas-siringa b'id waħda u dawwar il-labra ta' qies 27 mat-tarf tas-siringa bl-id l-oħra sakemm tissikka (ara Figura 4).
English: Antibodies directed against the receptor domains of rilonacept were detected by an ELISA assay in patients with CAPS after treatment with Rilonacept Regeneron in clinical studies.
Maltese: Antikorpi diretti kontra d-dominji tar-riċetturi ta' rilonacept kienu osservati permezz ta' assaġġ ELISA f'pazjenti bil-CAPS wara l-kura b'Rilonacept Regeneron fi studji kliniċi.
English: The combination of Rilonacept Regeneron with TNF inhibitors has not been evaluated in clinical studies.
Maltese: Il-kura b'Rilonacept Regeneron m'għandhiex tinbeda f'pazjenti bin-newtropenja.
English: • Headache
Maltese: • Garzi
English: Treatment should be initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg. Dosing should be continued with a once-weekly injection of 2.2 mg/kg, up to a maximum of 160 mg (see Table 1).
Maltese: Id-dożaġġ għandu jitkompla b'injezzjoni ta' 2.2 mg/kg darba kull ġimgħa sa massimu ta' 160 mg (ara Tabella 1).
English: • Gauze pads
Maltese: • Għeja kbira
English: • 4 vials of Rilonacept Regeneron powder
Maltese: Kunjett b'Rilonacept Regeneron
English: Let the alcohol air dry completely.
Maltese: Ħalli l-alkoħol jinxef kompletament.
English: The following items are included in each Rilonacept Regeneron dose pack:
Maltese: L-oġġetti li ġejjin huma inklużi f'kull pakkett dożat ta' Rilonacept Regeneron:
English: The following information is intended for medical or healthcare professionals only and is provided as a tear-off leaflet:
Maltese: Dan il-prodott mediċinali kien awtorizzat taħt ‘Ċirkustanzi ta' Eċċezzjoni”.
English: All cases in the clinical trials had a confirmed mutation in the NLRP3 gene.
Maltese: U KONTENUT Trab għal soluzzjoni għall-injezzjoni.
English: The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the medicinal product is on the market.
Maltese: Id-detentur tal-Awtorizzazzjoni għat-tqegħid fis-suq (MAH) għandu jiżgura li s-sistema ta' farmakoviġilanza ppreżentata f'Modulu 1.8.1. tal-Awtorizzazzjoni għat-Tqegħid fis-Suq, tkun fis-seħħ u tiffunzjona qabel u waqt li l-prodott mediċinali jkun fis-suq.
English: Eosinophil count increased common
Maltese: Żieda fl-għadd tal-esinofili komuni
English: • The need for Health Care Professionals to perform an annual clinical assessment of patients regarding a potential increased risk for the development of malignancies;
Maltese: • Il-ħtieġa li l-Professjonisti fil-Qasam tal-Kura tas-Saħħa jagħmlu evalwazzjoni klinika kull sena tal-pazjenti dwar żieda potenzjali fir-riskju għall-iżvilupp ta' tumuri malinni;
English: Because Rilonacept Regeneron dampens an inflammatory response, vigilance in excluding underlying infection in unwell patients is required.
Maltese: Indeboliment tal-fwied Rilonacept Regeneron ma ġiex studjat f'pazjenti b'indeboliment tal-fwied.
English: Although hypersensitivity reactions related to treatment with Rilonacept Regeneron were not seen in the initial clinical program, if a hypersensitivity reaction occurs, administration should be stopped immediately and permanently, and appropriate therapy initiated.
Maltese: Għalkemm reazzjonijiet ta' sensittività eċċessiva marbuta mal-kura b'Rilonacept Regeneron ma kinux osservati fil-programm kliniku inizjali, jekk isseħħ reazzjoni ta' sensittività eċċessiva, l-għoti għandu jitwaqqaf minnufih u b'mod permanenti u tinbeda terapija adattata.
English: • Meningitis
Maltese: Dijanjosi
English: Read these instructions all the way through before beginning.
Maltese: Id-data ta' meta tiskadi tirreferi għall-aħħar ġurnata ta' dak ix-xahar.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 08/01/2018.
Maltese: L-opinjoni tas-CHMP intbagħtet lill-Kummissjoni Ewropea, li ħarġet deċiżjoni vinkolanti legalment finali applikabbli fl-Istati Membri tal-UE kollha fi 08/01/2018.
English: Zinbryta contains the active substance daclizumab and was authorised in the EU in July 2016.
Maltese: Zinbryta fih is-sustanza attiva daclizumab u ġie awtorizzat fl-UE f'Lulju 2016.
English: On 9 November 2017, the European Medicines Agency (EMA) concluded its review of the multiple sclerosis medicine Zinbryta (daclizumab) and confirmed further restrictions to reduce the risk of serious liver damage.
Maltese: Fid-9 ta' Novembru 2017, l-Aġenzija Ewropea għall-Mediċini (EMA) ikkonkludiet ir-reviżjoni tagħha talmediċina tal-isklerożi multipla Zinbryta (daclizumab) u kkonfermat aktar restrizzjonijiet biex jitnaqqas ir-riskju ta' ħsara serja fil-fwied.
English: • In clinical trials, 1.7% of patients receiving Zinbryta had a serious liver reaction such as autoimmune hepatitis, hepatitis and jaundice.
Maltese: • Fil-provi kliniċi, 1.7 % tal-pazjenti li kienu qed jirċievu Zinbryta kellhom reazzjoni serja fil-fwied bħal epatite awtoimmuni, epatite u suffejra.
English: In clinical trials, 1.7% of patients receiving Zinbryta had a serious liver reaction.
Maltese: Fil-provi kliniċi, 1.7 % talpazjenti li kienu qed jirċievu Zinbryta kellhom reazzjoni serja fil-fwied.
English: • Contact your doctor immediately if you develop any signs and symptoms of liver problems, such as unexplained nausea (feeling sick), vomiting, abdominal pain, tiredness, loss of appetite, yellowing of the skin and eyes and dark urine.
Maltese: • Ikkuntattja lit-tabib tiegħek immedjatament jekk tiżviluppa xi sinjali u sintomi ta' problemi filfwied, bħal nawżja bla raġuni (tħossok ma tiflaħx), remettar, uġigħ addominali, għeja, nuqqas ta' aptit, sfurija tal-ġilda u tal-għajnejn u awrina skura.
English: • Zinbryta can cause unpredictable and potentially fatal immune-mediated liver injury.
Maltese: • Zinbryta jista' jikkawża korriment fil-fwied mhux previst u potenzjalment fatali medjat millimmunità.
English: Zinbryta is a medicine used to treat certain patients with relapsing forms of multiple sclerosis.
Maltese: Zinbryta huwa mediċina li tintuża biex tikkura ċerti pazjenti b'forom rikaduti ta' sklerożi multipla.
English: Several cases of serious liver injury including immune-mediated hepatitis and fulminant liver injury have been reported.
Maltese: Ġew irrappurtati diversi każijiet ta' ħsara serja fil-fwied inkluż epatite medjata millimmunità u korriment fil-fwied fulminanti.
English: • In view of the risk, the indication for Zinbryta is restricted to adult patients with relapsing forms of multiple sclerosis who have had an inadequate response to at least two disease modifying therapies (DMTs) and for whom treatment with any other DMT is contraindicated or otherwise unsuitable.
Maltese: • Fid-dawl tar-riskju, l-indikazzjoni għal Zinbryta hija ristretta għal pazjenti adulti b'forom rikaduti ta' sklerożi multipla li kellhom rispons inadegwat għal tal-inqas żewġ terapiji li jimmodifikaw il-marda (DMTs) u li għalihom kura b'xi DMT oħra hija kontraindikata jew inkella mhux xierqa.
English: The review of the liver effects of Zinbryta was conducted by EMA's Pharmacovigilance Risk Assessment Committee (PRAC), which issued recommendations in October 2017.
Maltese: Ir-reviżjoni tal-effetti fuq il-fwied ta' Zinbryta saret mill-Kumitat dwar il-Valutazzjoni tar-Riskji talFarmakoviġilanza (PRAC) tal-EMA, li ħareġ rakkomandazzjonijiet f'Ottubru 2017.
English: More information can be found on the medicine's dedicated page on EMA's website.
Maltese: Aktar informazzjoni tista' tinstab fuq il-paġna dedikata għall-mediċina fuq is-sit web tal-EMA.
English: The review of Zinbryta was initiated on 9 June 2017 at the request of the European Commission under Article 20 of Regulation (EC) No 726/2004.
Maltese: Ir-reviżjoni ta' Zinbryta nbdiet fid-9 ta' Ġunju 2017 fuq talba mill-Kummissjoni Ewropea, skont lArtikolu 20 tar-Regolament (KE) Nru 726/2004.
English: • Zinbryta can cause serious and life-threatening liver problems in some patients.
Maltese: • Zinbryta jista' jikkawża problemi fil-fwied serji u ta' theddid għall-ħajja f'xi pazjenti.
English: Zinbryta to be used in restricted patient group, with strict liver monitoring
Maltese: Zinbryta għandu jintuża fi grupp ta' pazjenti ristrett, b'monitoraġġ ristrett tal-fwied
English: − Exercise caution in patients taking other medicinal products with known hepatotoxic potential, including non-prescription products and herbal supplements.
Maltese: − Eżerċita l-kawtela f'pazjenti li jkunu qed jieħdu prodotti mediċinali oħrajn b'potenzjal epatotossiku magħruf, inkluż prodotti mhux bir-riċetta u supplimenti erbali.
English: The review found that unpredictable and potentially fatal immune-mediated liver injury can occur during treatment with Zinbryta and for up to 6 months after stopping treatment.
Maltese: Ir-reviżjoni sabet li jista' jseħħ korriment fil-fwied mhux previst u potenzjalment fatali medjat millimmunità waqt il-kura b'Zinbryta u sa 6 xhur wara t-twaqqif tal-kura.
English: − It is recommended that you stop treatment in patients with ALT or AST levels more than 3 times the ULN regardless of bilirubin levels.
Maltese: − Huwa rrakkomandat li twaqqaf il-kura f'pazjenti b'livelli ta' ALT jew AST aktar minn 3 darbiet tal-ULN irrispettivament mil-livelli tal-bilirubina.
English: • Your doctor will check your liver regularly (via a blood test), during treatment with Zinbryta and for up to 6 months after stopping treatment.
Maltese: • It-tabib tiegħek se jiċċekkja l-fwied tiegħek regolarment (permezz ta' test tad-demm), waqt il-kura b'Zinbryta u sa 6 xhur wara t-twaqqif tal-kura.
English: • You will be given a form to fill in to show that you understand the risk to the liver and the need for regular check-ups.
Maltese: • Int se tingħata formola biex timliha biex turi li tifhem ir-riskju għall-fwied u l-ħtieġa għal visti regolari.
English: The review was carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Maltese: Ir-reviżjoni saret mill-Kumitat dwar il-Valutazzjoni tar-Riskji tal-Farmakoviġilanza (PRAC), il-Kumitat responsabbli għall-evalwazzjoni ta' kwistjonijiet tas-sigurtà għall-mediċini għall-użu mill-bniedem, li għamel sett ta' rakkomandazzjonijiet.
English: − Screen patients for hepatitis B or C infection before starting treatment in new patients and refer those who test positive to a liver specialist.
Maltese: − Skrinja l-pazjenti għal infezzjoni tal-epatite B u Ċ qabel il-bidu tal-kura f'pazjenti ġodda u rreferi dawk li jkollhom riżultat pożittiv għal speċjalista tal-fwied.
English: − Monitor patients' serum transaminase and bilirubin levels at least monthly and as close as possible before each administration, and for up to 6 months after stopping treatment.
Maltese: − Immonitorja l-livelli tat-transaminase u tal-bilirubina fis-seru tal-pazjenti tal-inqas kull xahar u kemm jista' jkun viċin ta' xulxin qabel kull għoti, u sa 6 xhur wara t-twaqqif tal-kura.
English: The Committee for Medicinal Products for Human Use (CHMP) then adopted EMA's final opinion, which was sent to the European Commission for adoption of a legally binding decision.
Maltese: Il-Kumitat għallProdotti Mediċinali għall-Użu mill-Bniedem (CHMP) imbagħad adotta l-opinjoni finali tal-EMA, li ntbagħtet lill-Kummissjoni Ewropea għal adozzjoni ta' deċiżjoni legalment vinkolanti.
English: Zinbryta should now only be used in patients who have had an inadequate response to at least two disease modifying therapies (DMTs) and cannot be treated with any other DMTs.
Maltese: Issa Zinbryta għandu jintuża biss f'pazjenti li kellhom rispons inadegwat għal tal-inqas żewġ terapiji li jimmodifikaw il-marda (DMTs, disease modifying therapies) u li ma jistgħux jiġu kkurati b'xi DMT oħra.
English: − It is recommended that you do not start treatment in new patients with ALT or AST levels equal to or more than 2 times the upper limit of normal (ULN) or in patients with autoimmune conditions other than multiple sclerosis.
Maltese: − Huwa rrakkomandat li ma tibdiex il-kura f'pazjenti ġodda b'livelli ta' ALT jew AST daqs jew aktar minn darbtejn il-limitu ta' fuq tan-normal (ULN, upper limit of normal) jew f'pazjenti b'kondizzjonijiet awtoimmuni minbarra l-isklerożi multipla.
English: The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's opinion.
Maltese: Ir-rakkomandazzjonijiet tal-PRAC intbagħtu lill-Kumitat għallProdotti Mediċinali għall-Użu mill-Bniedem (CHMP), responsabbli għall-mistoqsijiet dwar il-mediċini għall-użu mill-bniedem, li adotta l-opinjoni tal-Aġenzija.
English: • These recommendations update provisional measures introduced in July 2017 which were communicated directly to healthcare professionals in the EU.
Maltese: • Dawn ir-rakkomandazzjonijiet jaġġornaw miżuri provviżorji introdotti f'Lulju 2017 li ġew ikkomunikati direttament lill-professjonisti tal-kura tas-saħħa fl-UE.
English: Further information on Activyl Tick Plus can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: This overview was last updated in March 2018.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Marzu 2018.
English: Other information about Activyl Tick Plus:
Maltese: Informazzjoni oħra dwar Activyl Tick Plus:
English: Activyl Tick Plus received a marketing authorisation valid throughout the EU on 9 January 2012.
Maltese: Activyl Tick Plus irċieva awtorizzazzjoni għat-tqegħid fis-suq valida fl-EU kollha fid-9 ta' Jannar 2012.
English: Activyl Tick Plus (indoxacarb / permethrin)
Maltese: Activyl Tick Plus (indoksakarb / permetrina)
English: In the other study, Activyl Tick Plus showed repellant activity of 98% at 2 days after treatment falling to 86% at 3 weeks.
Maltese: Fl-istudju l-ieħor, Activyl Tick Plus wera attività ta' repellent ta' 98% jumejn wara l-kura li niżlet għal 86% wara 3 ġimgħat.
English: The effectiveness of Activyl Tick Plus against sand flies was shown in two laboratory studies.
Maltese: L-effikaċja ta' Activyl Tick Plus kontra s-sand flies intweriet f'żewġ studji fil-laboratorji.
English: In one study, Activyl Tick Plus showed repellant activity of above 95% at 1 day after treatment, falling to 92% at 3 weeks after treatment.
Maltese: Fi studju wieħed, Activyl Tick Plus wera attività ta' repellent ta' ‘l fuq minn 95% fl-ewwel jum wara l-kura, li niżlet għal 92% wara fi tliet ġimgħat wara l-kura.
English: Activyl Tick Plus contains the active substances indoxacarb and permethrin.
Maltese: Activyl Tick Plus fih is-sustanzi attivi indoksakarb u permetrina.
English: The application of Activyl Tick Plus may produce a temporary oily appearance or hair clumping at the application site, or a dry white residue.
Maltese: L-applikazzjoni ta' Activyl Tick Plus jista' jipproduċi apparenza żejtnija temporanja jew telf ta' xagħar fis-sit tal-applikazzjoni, jew residwu abjad xott.
English: What are the risks associated with Activyl Tick Plus?
Maltese: X'inhuma r-riskji assoċjati ma' Activyl Tick Plus?
English: One field study involved 230 dogs where Activyl Tick Plus was compared with fipronil (another ectoparasiticide), where the medicines were given every four weeks for 12 weeks.
Maltese: Studju fuq il-post wieħed involva 230 kelb fejn Activyl Tick Plus tqabbel mal-fipronil (ektoparasitiċida ieħor), fejn il-mediċini ngħataw kull erbgħa ġimgħat għal 12-il ġimgħa.
English: The active substances in Activyl Tick Plus, indoxacarb and permethrin, are ectoparasiticides, which kill parasites such as fleas and ticks that may be found on the skin or in the fur of animals.
Maltese: Is-sustanzi attivi f'Activyl Tick Plus, l-indoksakarb u l-permetrina, huma ektoparasitiċidi, li joqtlu l-parassiti bħall-briegħed u l-qurdien li jistgħu jinstabu fuq il-ġilda jew fil-pil tal-annimali.
English: Activyl Tick Plus is a veterinary medicine used in dogs to treat flea and tick infestations.
Maltese: Activyl Tick Plus huwa mediċina veterinarja użata fil-klieb għall-kura ta' infestazzjonijiet tal-briegħed u tal-qurdien.